Navigation Links
Tuberculosis genomes portray secrets of pathogen's success

MADISON, Wis. By any measure, tuberculosis (TB) is a wildly successful pathogen. It infects as many as two billion people in every corner of the world, with a new infection of a human host estimated to occur every second.

Now, thanks to a new analysis of dozens of tuberculosis genomes gathered from around the world, scientists are getting a more detailed picture of why TB is so prevalent and how it evolves to resist countermeasures. Writing today (Aug. 21, 2013) in the journal Public Library of Science (PLoS) Pathogens, a team led by University of Wisconsin-Madison researcher Caitlin Pepperell describes a bacterium that marches in lockstep with human population growth and history, evolving to take advantage of the most crowded and wretched human conditions.

"It's as though the bacterium places bets on human behavior," says Pepperell, formerly of Stanford University, and now a professor of medicine and medical microbiology at UW-Madison. "It always bets that humans will go to war, send people to refugee camps, and gather in miserable places. Historically, that's been a winning bet on the bacterium's part."

The PLoS Pathogens study, whose senior author is Marcus Feldman of Stanford, reveals that tuberculosis experienced a 25-fold expansion worldwide in the 17th century, a time when human populations underwent explosive growth and European exploration of Africa, the Americas, Asia and Oceania was at its peak.

"The timing is coincident with expansion, urbanization and colonial migrations of global human populations," Pepperell explains. "These findings suggest that much of the current TB pandemic has its origins in historical events of the last three centuries."

TB is only transmitted by people, and the organism cannot survive in the environment. It thrives, however, in the crowded conditions of prisons, refugee camps and slums, and TB populations tend to be dominated by the bacteria "lucky" enough to land in those environments.

The analysis conducted by Pepperell and her colleagues focused on the role of natural selection, looking at patterns of genetic diversity among 63 TB and related pathogenic mycobacterial genomes gathered from around the globe.

The study shows a highly constrained bacterial genome, with most deleterious mutations quickly discarded. This was especially true for genes essential for causing disease, protein translation and the trafficking and metabolism of inorganic ions, which help control the interaction between the TB pathogen and its human host.

The bacterium's "defense" genes, on the other hand, showed a high degree of tolerance for beneficial mutations, which may play a role in evolution of drug resistance and evasion of the human immune system.

Pepperell notes: "Evolutionary theory predicts that Mycobacterium tuberculosis populations should be vulnerable to extinction. Yet it is obviously highly prevalent. It must have some incredibly clever strategies and tricks to hang on."

As a result, the explosive spread of TB parallels the growth of human populations and takes every advantage of a world where most people live in crowded and impoverished conditions.

The study, according to Pepperell, should help other researchers home in on genes that may be good candidates for targeting with new drugs, and aid disease control strategies that accommodate or even co-opt the bacterium's evolution and help drive its extinction.


Contact: Caitlin Pepperell
University of Wisconsin-Madison

Related biology news :

1. Biosignatures distinguish between tuberculosis and sarcoidosis
2. Targeting tuberculosis hotspots could have widespread benefit
3. MIT-designed cooler preserves tuberculosis drugs, records doses
4. Research on improvements in diagnosing and treating tuberculosis
5. Millions of diabetics could die of tuberculosis
6. New approach of resistant tuberculosis
7. Iowa State, Ames Lab researchers study the structure of drug resistance in tuberculosis
8. High doses of Vitamin D help tuberculosis patients recover more quickly
9. Scientists reveal how natural antibiotic kills tuberculosis bacterium
10. Notre Dame research could provide new insights into tuberculosis and other diseases
11. Missing link discovered in the defence mechanism of the tuberculosis pathogen
Post Your Comments:
(Date:4/26/2016)... India and LONDON ... Infosys Finacle, part of EdgeVerve Systems, a product ... and Onegini today announced a partnership to integrate ... solutions.      (Logo: ... to provide their customers enhanced security to access ...
(Date:4/15/2016)... , April 15, 2016  A new ... make more accurate underwriting decisions in a fraction ... timely, competitively priced and high-value life insurance policies ... screenings. With Force Diagnostics, rapid testing ... lifestyle data readings (blood pressure, weight, pulse, BMI, ...
(Date:4/13/2016)... -- IMPOWER physicians supporting Medicaid patients in Central ... in telehealth thanks to a new partnership with higi. ... patients can routinely track key health measurements, such as ... when they opt in, share them with IMPOWER clinicians ... retail location at no cost. By leveraging this data, ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... , ... June 24, 2016 , ... While the majority ... as the Cary 5000 and the 6000i models are higher end machines that use ... height of the spectrophotometer’s light beam from the bottom of the cuvette holder. ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge (BDC), ... new ways to harness living systems and biotechnology, announced ... (MoMA) in New York City . ... participating students, showcased projects at MoMA,s Celeste Bartos Theater ... Antonelli , MoMA,s senior curator of architecture and design, ...
(Date:6/23/2016)... LOUISVILLE, Ky. , June 23, 2016 /PRNewswire/ ... from two Phase 1 clinical trials of its ... double-blind, placebo-controlled, single and multiple ascending dose studies ... and pharmacodynamics (PD) of subcutaneous injection in healthy ... APL-2 subcutaneously (SC) either as a single dose ...
Breaking Biology Technology: